Clinical Trials Browser

Lung Neoplasms × lazertinib × Thoracic × Clear all

NCT05701384 2023-01-27

Lazertinib 160mg in EGFR T790M NSCLC

Phase 2 Unknown

Lung Neoplasms

NCT04829422 2022-03-03

Early Access Program of Lazertinib in Republic of Korea

Approved for marketing

Lung Neoplasms